Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PD-1 Inhibitor for Early-stage HCC Following Microwave Ablation
NCT06248554Completed
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Open-label trial in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Disease-free survival at 60 months. Started Jan 2021; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06248554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248554.